KRAS is mutated in nearly a quarter of a wide spectrum of cancers, NRAS is mutated in <10% of cancers, but at a high frequency in specific cancers, while HRAS is rarely mutated in any cancer2–4,6. This evidence concerns the gene KRAS and cancer.